EGFR and non-small cell lung carcinoma: For unresectable stage III NSCLC with EGFR mutations, osimertinib treatment after chemoradiation significantly prolonged PFS, yet there was no notable difference in 3-year overall survival rates.214 Currently, various alternative strategies, such as single-agent and dual-agent ICIs,215 or ICIs combined with anti-angiogenic drugs, used either concurrently216–218 or sequentially218,219 with radiation therapy alone or concurrent chemoradiotherapy, are under investigation to determine if these treatments bring about benefits.